The Ministry of Health and Family Welfare in India has proposed a separate licensing framework for the wholesale trade of bulk drugs, including active and inactive substances, aiming to enhance regulatory oversight and accountability within the pharmaceutical supply chain. The proposed amendments to the Drugs Rules, 1945, will introduce distinct application and license forms for the wholesale of bulk drugs, separate from the existing licensing provisions for formulations. Currently, a single license covers both formulations and bulk drug wholesale. This amendment aims to establish a dedicated framework for bulk drugs, ensuring more targeted regulatory oversight and accountability in their wholesale trade. The proposal was approved by the Drugs Consultative Committee on November 17, 2025, and the Drugs Technical Advisory Board on February 16, 2026. Under the proposed framework, wholesalers handling bulk drugs will be licensed, capturing the categories of drugs involved, including those covered under the Narcotic Drugs and Psychotropic Substances Act, 1985. The sale of bulk drugs will be supervised by competent personnel, improving accountability in their distribution and handling. Upon implementation, this amendment is expected to provide better control over the wholesale of bulk drugs, strengthening enforcement control related to antimicrobial resistance and the movement of NDPS drugs. Existing licensees will be given a reasonable time to comply with the new provisions. The ministry invites objections and suggestions from stakeholders within 30 days following the publication of the draft rules.

SUMMARY (Cont'd):

The proposed framework seeks to improve regulatory oversight and accountability in the wholesale trade of bulk drugs, which are essential components in pharmaceutical production. The ministry hopes that this dedicated licensing framework will lead to a more efficient and transparent supply chain, benefiting both manufacturers and consumers alike. It is important to note that this article is based on an automated news agency feed without modifications to the text.

SUMMARY (Cont'd):

The proposed amendments aim to address concerns regarding regulatory oversight and accountability in the wholesale trade of bulk drugs, which are vital components in the production of pharmaceuticals. By establishing a dedicated licensing framework, the ministry hopes to foster a more efficient, transparent, and controlled supply chain, ultimately benefiting both manufacturers and consumers. The proposed changes will become applicable upon expiry of the current retention period or 12 months after the final publication of the amendment, whichever is later. The ministry encourages stakeholders to provide their feedback within the specified timeframe.